Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features by Møller, Michael Boe et al.
Hematopathology / CYCLIN D3 EXPRESSION IN NON-HODGKIN LYMPHOMA
404 Am J Clin Pathol 2001;115:404-412    © American Society of Clinical Pathologists
Cyclin D3 Expression in Non-Hodgkin Lymphoma
Correlation With Other Cell Cycle Regulators and Clinical Features
Michael B. Møller, MD,1,2 Ole Nielsen,1 and Niels T. Pedersen, MD, PhD1,2
Key Words: Lymphoma; Cyclin D3; p27Kip1; p21Waf1; p53; MDM2; Immunohistochemistry; Prognosis
A b s t r a c t
Cyclin D3 is the most widely expressed D-type
cyclin and can be rate limiting for G1/S transition. To
study the expression of cyclin D3 in non-Hodgkin
lymphoma, samples from 198 previously untreated
patients with lymphoma from a prospectively collected,
population-based lymphoma registry were analyzed
immunohistochemically for cyclin D3 expression. In 43
lymphomas (21.7%), cyclin D3 was overexpressed. T-
cell lymphomas more frequently overexpressed cyclin
D3 than B-cell lymphomas. Furthermore, cyclin
D3–overexpressing indolent lymphomas were
associated with higher proliferation rate, higher p21Waf1
expression, lower p27Kip1 expression, and altered p53.
Cyclin D3 overexpression identified a subgroup of
patients with indolent B-cell lymphoma with adverse
clinical features: patients were older, more frequently
had “B” symptoms and extranodal involvement, and
were more frequently in the high-intermediate or high-
risk International Prognostic Index groups. At
univariate analysis of indolent lymphomas, cyclin D3
overexpression was associated significantly with poor
overall survival and poor relapse-free survival. The
statistical significance was retained on multivariate
analysis of overall survival and relapse-free survival.
Our results suggest that cyclin D3 is expressed
differentially among lymphoma subtypes and that
overexpression might identify a subpopulation of
patients with indolent lymphoma with adverse clinical
features and poor outcome.
Cell division and proliferation are controlled tightly in
human cells. A prerequisite of cancer cells is evasion of this
control.1 A common target of tumorigenesis is, therefore, the
biochemical pathway regulating the G1/S transition, as cells
that have progressed to the S phase are committed to cell
division. Central to the regulation of G1/S transition is the
phosphorylation of the retinoblastoma protein, pRB. pRB is
phosphorylated by cyclin-dependent kinases (CDKs), whose
activity depends on complex formation with cyclin. CDK
inhibitors (CDKIs) inhibit the cyclin-CDK complexes. The
pRB phosphorylation is sequential—initiated by cyclin
D–CDK4/6 complexes and completed by cyclin E/CDK2.2
The D-type cyclins (cyclin D1, D2, and D3) link mito-
genic signals to the cell cycle machinery by being up-regu-
lated by extracellular growth-promoting signals.1 They are
essential to G1 progression and can be rate limiting for G1/S
transition.3,4 The D-type cyclins are expressed in a tissue-
specific way, and cyclin D3 is the most widely expressed D-
type cyclin.4
D-type cyclins are implicated in tumorigenesis. Trans-
genic experiments have disclosed transforming functions of
cyclin D1 and cyclin D2.5-9 In human lymphomas, the mantle
cell lymphoma characteristic t(11;14) leads to cyclin D1 over-
expression.10 Cyclin D2 is overexpressed in other subsets of
lymphomas.11,12 Cyclin D3 is also an attractive candidate
oncogene for lymphomagenesis. In nonneoplastic lymphoid
tissues, cyclin D3 expression correlates positively with prolif-
eration.4 The 6p21 region, which encompasses the cyclin
D3–encoding CCDN3 gene, is amplified in a fraction of follic-
ular lymphomas.13 Furthermore, cyclin D3 is overexpressed in
subsets of low-grade and high-grade lymphomas.12,14-17 The
prognostic significance of cyclin D3 overexpression in
lymphomas and other tumors has not been studied.
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Our aim was to study cyclin D3 expression in 198
patients from a prospective, population-based lymphoma
registry who had clinically well-characterized non-Hodgkin
lymphoma (NHL). Some of the tumors were studied previ-
ously for alterations of other proteins (p27Kip1, p21Waf1, p53,
MDM2) involved in cell cycle regulation, thereby enabling
analysis of correlations between cyclin D3 expression and
these molecular variables. Furthermore, the association of
cyclin D3 expression with clinical features and outcome was
assessed.
Materials and Methods
Patients
Initially, the study included 206 previously untreated
patients, with a diagnosis of NHL, from the prospectively
collected, systematically followed up, population-based NHL
database registry of the Danish Lymphoma Group (LYFO).
The cases were obtained by including consecutive cases from
each of the major histologic NHL subtypes from a single
institution. The cases were diagnosed between January 1,
1984, and December 31, 1994. The LYFO registry, including
exclusion criteria, hematopathologic analysis, staging, and
follow-up procedures, was described previously.18 Eight
patients were excluded from the study because no tissue from
the time of diagnosis was available for immunohistochemical
analysis (2 patients) or clinical data were insufficient for
calculation of the International Prognostic Index (IPI; 6
patients).19 The lymphomas were reclassified according to
the Revised European-American Lymphoma classification20
and grouped clinically as proposed by Hiddemann et al.21
Our final study population was classified as follows: 71 indo-
lent B-cell lymphomas (B-cell small lymphocytic lymphoma,
13 cases; immunocytoma, 18 cases; follicle center lymphoma
[FCL], follicular grade I/II, 21 cases; and extranodal
marginal zone lymphoma, 19 cases), 74 aggressive B-cell
lymphomas (FCL, follicular grade III, 4 cases; FCL, diffuse,
3 cases; mantle cell lymphoma, 18 cases; and diffuse large B-
cell lymphoma [DLCL], 49 cases), 37 aggressive T-cell
lymphomas (peripheral T-cell lymphoma [unspecified, 21;
angioimmunoblastic, 6; angiocentric, 1; intestinal T-cell
lymphoma, 1]; and anaplastic large T-cell or null-cell
lymphoma, 8 cases), and 16 very aggressive lymphomas (B-
cell lymphoblastic lymphoma, 5 cases; Burkitt lymphoma, 3
cases; and T-cell lymphoblastic lymphoma, 8 cases). The
observation period analyzed was up to 5 years, until
December 31, 1996, or death, whichever came first. No
patients were lost to follow-up. The median follow-up period
for patients alive at the end of the observation period was 60
months (range, 36-60 months). The main clinical characteris-
tics of the patients are summarized in ❚Table 1❚. Correlation
between cyclin D3 expression and clinical characteristics and
patient outcome was analyzed using the following variables:
age; sex; performance status (according to Eastern Coopera-
tive Oncology Group); extranodal disease; “B” symptoms;
serum albumin concentration; hemoglobin level; WBC and
platelet counts; serum concentrations of creatinine, bilirubin,
alanine aminotransferase, alkaline phosphatase, iron, and
transferrin; treatment (combination chemotherapy/single
alkylating agent/other) and treatment response; relapse-free
survival; and overall survival.
All patients were treated according to the common
general guidelines of LYFO, resulting in a rather homoge-
neous treatment background. The 71 indolent lymphomas
were treated with combination chemotherapy in 26 cases (20
including anthracycline), single alkylating agents in 22 cases,
radiotherapy and/or surgery in 21 cases, and no treatment in
2 cases. Forty-eight patients treated with chemotherapy had
advanced-stage NHL, whereas 19 of 21 patients treated with
radiotherapy and/or surgery had stage I or II disease (P <
.001). Aggressive B-cell lymphomas were treated with
combination chemotherapy in 60 cases (anthracycline-
containing in 48 cases, primarily cyclophosphamide, doxoru-
bicin, vincristine, and prednisone), single alkylating agents
in 6 cases, and other approaches in 8 cases. Treatment of the
aggressive T-cell lymphomas was combination chemo-
therapy for 28 patients, with (24 cases) or without (4 cases)
anthracycline. Two patients received radiotherapy, 4 patients
were treated with interferon or prednisone, and 3 patients
had no initial therapy. Fifteen of 16 very aggressive
lymphomas were treated with high-dose combination
chemotherapy with central nervous system prophylaxis in 12
cases. One patient died before therapy was instigated.
Complete response was defined as complete disappearance
of tumor masses, and partial remission was defined as
decrease by at least 50% of the tumor masses along with
resolution of disease-related symptoms.
To determine whether the present study population was a
representative sample of the whole population-based LYFO
population, we compared our study population (overall and
for each histologic subtype) with the remaining patients in the
LYFO registry who were given diagnoses in the same time
period (n = 3,014). No significant differences were identified
between the 2 populations in age, sex, stage, performance
score, B symptoms, serum lactate dehydrogenase level,
number of extranodal sites involved, complete response rates,
or overall survival. Furthermore, the distribution of IPI risk
group assignment was not significantly different between the
study population and the remaining LYFO patients.
Immunohistochemical Studies
Our assay for immunohistochemical staining for
cyclin D3 has been described.22 Briefly, sections from the
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paraffin-embedded formalin-fixed lymphoma samples and
samples of 8 reactive lymphoid tissues were subjected to
microwave-based heat-induced antigen retrieval, followed by
immunohistochemical analysis of cyclin D3 expression using
the anti–cyclin D3 antibody DCS-22 (Novocastra, Newcastle
upon Tyne, England) diluted to 1:20 and incubated
overnight. A sensitive, labeled streptavidin-avidin-biotin
detection method (ChemMate-Peroxidase/DAB; DAKO,
Glostrup, Denmark) was used on an automated staining
machine (TechMate 1000, DAKO). Sections from reactive
lymphoid tissue served as positive controls. The percentage
of cells with immunoreactive nuclei was evaluated with an
image analysis system.23 Typically, 1,000 to 3,000 cells from
the region of highest immunoreactivity were counted by use
of Image-Pro Plus software (Media Cybernetics, Silver
Spring, MD). The same observer, who was without knowl-
edge of the clinical data, reviewed all slides.
Clinically informative criteria for scoring immunohisto-
chemical expression of cyclin D3 have not been established.
Therefore, we analyzed several cutoff points for cyclin D3
expression for clinical significance and found superior segre-
gation into prognostic groups by a cutoff value of 5%. There-
fore, this cutoff point was used throughout the present study,
and cases with cyclin D3 immunoreactivity in 5% or more of
tumor nuclei were considered positive for cyclin D3. To
study reproducibility of cyclin D3 evaluation, a random
selection of 13 cases was scored twice with an interval of 3
weeks. All tumors were allocated to the same cyclin D3 cate-
gory in both scoring rounds.
The proliferation rate, using the MIB-1 antibody for
identification of the Ki-67 antigen, as well as p27Kip1,
p21Waf1, p53, and MDM2 expression, previously had been
determined in most patients by way of immunohistochemical
methods24-26 and, therefore, could be correlated with cyclin
D3 expression. Furthermore, the Deltap53 immunohisto-
chemical phenotype (p53 20% or more or a combination of
p53 >5% and negative p21Waf1), strongly associated with p53
missense mutation in lymphoma,25 also was correlated with
❚Table 1❚
Clinical Characteristics and Cyclin D3 Expression in 198 Patients With Non-Hodgkin Lymphoma
Cyclin D3 Expression
No. of Patients No. (%) at <5% No. (%) at 5% or More P
Age, y .097
<60 93 68 (73) 25 (27)
60 or older 105 87 (83) 18 (17)
Sex .527
Male 116 89 (77) 27 (23)
Female 82 66 (80) 16 (20)
Eastern Cooperative Oncology Group performance status .782
<2 146 115 (79) 31 (21)
2 or more 52 40 (77) 12 (23)
Clinical group <.001
Indolent 71 63 (89) 8 (11)
Aggressive B-cell 74 62 (84) 12 (16)
Aggressive T-cell 37 24 (65) 13 (35)
Very aggressive 16 6 (38) 10 (62)
Phenotype .003
B cell 153 127 (83) 26 (17)
T/Null cell 45 28 (62) 17 (38)
Ann Arbor stage .708
I/II 78 60 (77) 18 (23)
III/IV 120 95 (79) 25 (21)
Extranodal sites .087
0-1 172 138 (80) 34 (20)
>1 26 17 (65) 9 (35)
Bone marrow infiltration .078
No 139 104 (75) 35 (25)
Yes 58 50 (86) 8 (14)
Serum lactate dehydrogenase concentration .115
Normal 139 113 (81) 26 (19)
High 59 42 (71) 17 (29)
“B” symptoms .079
No 141 115 (82) 26 (18)
Yes 57 40 (70) 17 (30)
International Prognostic Index .136 
Low 77 57 (74) 20 (26)
Low intermediate 71 62 (87) 9 (13)
High intermediate 34 25 (74) 9 (26)
High 16 11 (69) 5 (31)  
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cyclin D3 expression. The immunostains were evaluated
using an image analysis system as described.
Statistical Analysis
Univariate association was analyzed using the Fisher
exact test, the Pearson chi-square test, or the Kruskal-Wallis
test. Overall survival was calculated from time of definitive
diagnosis to death from any cause during or to the end of the
observation. Relapse-free survival of patients with treatment
response (complete response or partial remission) was calcu-
lated from the time of achievement of complete response or
partial remission to relapse, death, or the end of the follow-
up period. Survival curves were calculated using the method
of Kaplan and Meier and compared using the log-rank test.
Factors independently affecting overall survival or relapse-
free survival were identified using a Cox proportional
hazards regression model (P = .10 or less for entry into the
model and to remain in the model). All P values were 2-
sided and considered significant if less than .05. SPSS for
Windows, version 9.0.0 (SPSS, Chicago, IL), was used for
all calculations.
Results
Cyclin D3 Expression
In the reactive lymphoid tissues the mean cyclin D3
expression was 3.15% (range, 0.24%-8.16%), 0.28% (range,
0.00%-1.81%), and 0.70% (range, 0.00%-1.76%) in germinal
centers, mantle zones, and interfollicular areas, respectively.
In reactive tissues and indolent lymphomas, the immunoreac-
tive cells were primarily large lymphoid cells ❚Image 1❚.
Forty-three tumors (21.7%) were positive for cyclin D3.
Cyclin D3 positivity was associated significantly with clinical
❚Image 1❚ Patterns of cyclin D3 protein expression in different
lymphoid tissues. A, A reactive lymph node with scattered
positive cells in a germinal center (diaminobenzidine, original
magnification ·400). B, A cyclin D3–negative (1% of cells
positive) small lymphocytic lymphoma with sparse expres-
sion in a proliferation center (diaminobenzidine, original
magnification ·400). C, Cyclin D3–positive (47% of cells posi-
tive) precursor T-cell lymphoblastic lymphoma with intense
cyclin D3 expression (diaminobenzidine, original magnifica-
tion ·400).
A B
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group, being most frequent in aggressive T-cell and very
aggressive lymphomas (Table 1 and Image 1). Moreover,
cyclin D3 overexpression was present more frequently in T-
cell than in B-cell lymphomas (38% vs 17%; P = .003).
The expression of cyclin D3 is given according to histo-
logic subtype in ❚Table 2❚. As indicated, cyclin D3 generally
was more frequently positive in lymphoma subtypes with a
higher proliferation rate. Therefore, it is noteworthy that
none of the mantle cell lymphomas were positive.
Cyclin D3 and Clinical Characteristics
Patients with cyclin D3–positive lymphoma were
younger than patients with cyclin D3–negative lymphoma
(mean age, 53 years vs 61 years, respectively; P = .028).
When the analysis was restricted to the 71 patients with indo-
lent B-cell lymphoma, an age difference was still apparent.
However, in this group, the 8 patients with cyclin D3–posi-
tive lymphoma were older than their 63 counterparts with
cyclin D3–negative lymphoma (mean age, 70 years vs 60
years; P = .048). Furthermore, patients with cyclin D3–posi-
tive indolent lymphoma more frequently had B symptoms
(50% vs 16%; P = .022) and involvement of more than 1
extranodal site (38% vs 7%; P = .027). Accordingly, patients
with cyclin D3–positive indolent lymphoma compared with
their counterparts with cyclin D3–negative lymphoma were
more frequently in the IPI high-intermediate or high-risk
groups (62% vs 15%; P = .001). Analysis restricted to each
of the other clinical groups, as well as to DLCL or peripheral
T-cell lymphoma, did not identify significant relations
between cyclin D3 expression and clinical variables.
Relationship Between Cyclin D3 Expression and
Proliferation, p27Kip1, and p21Waf1 Expression
❚Table 3❚ details the correlation of cyclin D3 status with
other cell cycle-related markers. Overall, the cyclin D3–posi-
tive tumors showed a significantly higher mean proliferation
rate than the cyclin D3–negative tumors (59% vs 39%; P <
.001). The association was maintained in analyses restricted
to B-cell lymphomas (P = .001) and to indolent lymphomas
(P = .048).
Cyclin D3 positivity also correlated with p21Waf1 expres-
sion. In the whole series, the cyclin D3–positive lymphomas
showed an average percentage of tumor cells expressing
p21Waf1 of 6.7% compared with 1.9% in cyclin D3–negative
lymphomas (P = .001). Also, in the subsets of patients with
indolent lymphomas (0.8% vs 3.3%; P = .006) and aggressive
B-cell lymphomas (1.9% vs 11.8%; P = .006), the expression
of p21Waf1 was higher in cyclin D3–positive tumors.
For the subsets of patients with indolent lymphoma, the
percentage of p27Kip1-positive tumor cells was significantly
lower (P = .015) in cyclin D3–positive lymphomas than in
cyclin D3–negative lymphomas. Conversely, in aggressive
B-cell lymphoma, the percentage of p27Kip1-positive tumor
cells was significantly higher in cyclin D3–positive
lymphomas (P = .047). Previous studies have shown that a
subset of aggressive and very aggressive lymphomas with
high p27Kip1 expression and high proliferation rates often
were positive for cyclin D3.16 We therefore analyzed the
correlation between cyclin D3 expression and high expres-
sion of p27Kip1 (>40% of tumor cells immunopositive) in the
subset of aggressive and very aggressive lymphomas with a
proliferation rate exceeding 50% (n = 78). The mean
percentage of cyclin D3 expression was 32% in 7
lymphomas with high p27Kip1 expression compared with 8%
in 71 cases with low p27Kip1 expression (P = .003).
Relationship Between Cyclin D3 Expression and p53
Status and MDM2 Expression
Analyzing the whole series, cyclin D3 expression did
not significantly correlate with Deltap53. However, for the
68 indolent lymphomas for which Deltap53 status was avail-
able, Deltap53 (n = 13) was associated with higher cyclin D3
expression (mean cyclin D3 percentage, 7% vs 1%, respec-
tively; P = .036).
Overexpression of the p53-regulating oncoprotein
MDM2 (defined as its expression in 10% or more of the
❚Table 2❚
Cyclin D3 Expression in Non-Hodgkin Lymphoma According to the Histologic Subtype
Cyclin D3 Expression (Percentage of Cells)
Subtype No. of Patients Mean Range No. (%) of Patients Cyclin D3+
Small lymphocytic 13 0.2 0-1 0 (0)
Immunocytoma 18 2.3 0-18 4 (22)
Follicle center 28 1.3 0-9 2 (7)
Extranodal marginal zone 19 5.0 0-63 3 (16)
Mantle cell 18 0.4 0-4 0 (0)
Diffuse large cell 49 5.0 0-58 11 (22)
Peripheral T-cell 29 7.1 0-32 11 (38)
Anaplastic large cell 8 14.3 0-85 2 (25)
Lymphoblastic/Burkitt 16 25.1 0-85 10 (62) 
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tumor cells; data available for 183 cases in the present series)
correlated with increased cyclin D3 expression overall (P =
.005) and in the subset of DLCL (n = 46; P = .051).
Relapse-Free Survival
The 5-year relapse-free survival rates according to
cyclin D3 expression for the whole series, as well as for the
subsets of indolent, aggressive B-cell, aggressive T-cell, and
very aggressive lymphomas, are given in ❚Table 4❚. Cyclin
D3 expression was associated significantly with lymphoma
recurrence (P = .0016) ❚Figure 1❚ in the group of indolent
lymphomas. In contrast, in the subsets of aggressive and very
aggressive lymphomas, patients with cyclin D3 expression
tended to have longer relapse-free survival. However, this
association did not reach statistical significance.
Multivariate analysis (including the IPI variables, histo-
logic subtype, treatment strategy, and cyclin D3 positivity) of
the cases of indolent lymphoma revealed that only cyclin D3
expression (relative risk [RR], 4.6; 95% confidence interval
[CI], 1.7-12.4; P = .0022), performance score (RR, 7.1; 95%
CI, 2.8-18.0; P < .0001), treatment (RR, 0.5; 95% CI, 0.3-
0.8; P = .0012), and extranodal involvement (RR, 0.2; 95%
CI, 0.06-0.8; P = .0214) were independent predictors of
relapse-free survival.
Overall Survival
The 5-year overall survival rate for the series was 44%
(SE, 0.035). Univariate analysis restricted to the 71 indolent
lymphoma cases showed that patients with cyclin D3–posi-
tive lymphoma had decreased 5-year survival probability
compared with patients with cyclin D3–negative lymphoma
(25% vs 55%; P = .0283) ❚Figure 2❚. Neither proliferation
rate nor histologic subtype was associated with survival,
which contradicts the suggestion that the association of
cyclin D3 with survival was merely a reflection of prolifera-
tion rate or histologic subtype of the cyclin D3–positive
indolent lymphomas. No significant relation between cyclin
D3 and overall survival was found for the other clinical
groups.
A Cox proportional hazards model including the IPI
variables, histologic subtype, treatment strategy, and cyclin
D3 positivity showed that cyclin D3 expression (RR, 3.0;
95% CI, 1.2-7.7; P = .0224), performance score (RR, 3.8;
95% CI, 1.8-8.0; P = .0004), stage (RR, 3.8; 95% CI, 1.5-9.2;
P = .0037), and age (RR, 2.8; 95% CI, 1.1-6.8; P = .0292)
were the only statistically significant covariates.
We did not include molecular variables other than cyclin
D3 in the outcome analyses described. The reason was that
the patients from the present series only partially overlapped
with those studied for other molecular markers (proliferation,
p27Kip1, p21Waf1, p53, and MDM2) and for whom all the
needed staging and follow-up data were available. However,
an analysis of cases fulfilling these criteria and, thus, studied
for cyclin D3 and additional markers did not reveal prog-
nostic significance of combinations of markers (data not
shown).
Discussion
Cyclin D3 is a cell cycle regulatory protein important
for G phase progression and G1/S transition. Cyclin D3 is
expressed in cancers of various histogenesis, including
lymphomas.12,14-17 Initially, the putative oncogenic function
of cyclin D3 was to form complexes with CDK4/6, thereby
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❚Figure 1❚ Relapse-free survival of 53 patients with indolent
lymphoma grouped into 2 classes of cyclin D3 expression
(<5%, 46 patients; 5% or more, 7 patients). P = .0016.
❚Figure 2❚ Overall survival of 71 patients with indolent
lymphoma grouped into 2 classes of cyclin D3 expression
(<5%, 63 patients; 5% or more, 8 patients). P = .0283.
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promoting pRB phosphorylation. However, recent studies
have indicated an additional potentially oncogenic function
of cyclin D3. In subsets of aggressive lymphomas and breast
cancer, cyclin D3 forms complexes with CDKIs of the
KIP/CIP family, p27Kip1 and p21Waf1.16,17,27 It is hypothesized
that the formation of these complexes sequesters and thereby
inhibits the antiproliferative function of p27Kip1 and p21Waf1.
In the present study, we showed a positive correlation
❚Table 4❚
Overall and Relapse-Free Survival According to Cyclin D3 Expression
5-Year Overall Survival 5-Year Relapse-Free Survival
Clinical Group/Cyclin D3 Expression No. of Patients Survival, % P No. of Patients Survival, % P
Overall series .9926 .7228
Negative 155 43 114 31
Positive 43 46 34 41
Indolent B-cell .0283 .0016
Negative 63 55 46 36
Positive 8 25 7 0
Aggressive B-cell .0921 .0909
Negative 62 35 46 35
Positive 12 67 10 70 
Aggressive T-cell .6795 .7659 
Negative 24 29 16 0
Positive 13 31 10 20
Very aggressive .8697 .2310
Negative 6 50 6 33
Positive 10 60 7 71  
❚Table 3❚
Correlation of Cyclin D3 Status With Other Cell Cycle–Related Proteins* for Each Histologic Subtype
p53 p21Waf1 Deltap53 MDM2
Subtype/Cyclin D3 Status 20% or No. 1% or No. No. 10% or No.
(No. of Patients) <20%† More† ND <1%† More† ND No† Yes† ND <10%† More† ND
Small lymphocytic
Negative (n = 13) 13 (100) 0 (0) 0 13 (100) 0 (0) 0 12 (92) 1 (8) 0 12 (100) 0 (0) 1
Positive (n = 0)
Immunocytoma
Negative (n = 14) 12 (92) 1 (8) 1 8 (62) 5 (38) 1 10 (83) 2 (17) 2 11 (92) 1 (8) 2
Positive (n = 4) 3 (75) 1 (25) 0 1 (25) 3 (75) 0 3 (75) 1 (25) 0 3 (100) 0 (0) 1
Follicle center
Negative (n = 26) 22 (85) 4 (15) 0 21 (81) 5 (19) 0 19 (73) 7 (27) 0 23 (89) 3 (12) 0
Positive (n = 2) 2 (100) 0 (0) 0 1 (50) 1 (50) 0 1 (50) 1 (50) 0 2 (100) 0 (0) 0
Extranodal marginal zone
Negative (n = 16) 14 (88) 2 (12) 0 10 (67) 5 (33) 1 12 (80) 3 (20) 1 16 (100) 0 (0) 0
Positive (n = 3) 1 (33) 2 (67) 0 1 (33) 2 (67) 0 1 (33) 2 (67) 0 2 (67) 1 (33) 0
Mantle cell
Negative (n = 18) 15 (100) 0 (0) 3 15 (83) 3 (17) 0 14 (93) 1 (7) 3 12 (86) 2 (14) 4
Positive (n = 0) — — — — — — — — — — — —
Diffuse large cell
Negative (n = 38) 29 (76) 9 (24) 0 18 (47) 20 (53) 0 26 (68) 12 (32) 0 20 (57) 15 (43) 3
Positive (n = 11) 8 (73) 3 (27) 0 3 (27) 8 (73) 0 8 (73) 3 (27) 0 3 (27) 8 (73) 0
Peripheral T-cell
Negative (n = 18) 16 (89) 2 (11) 0 3 (17) 15 (83) 0 16 (89) 2 (11) 0 16 (89) 0 (0) 2
Positive (n = 11) 10 (91) 1 (9) 0 3 (27) 8 (73) 0 9 (82) 2 (18) 0 9 (82) 2 (18) 0
Anaplastic large cell
Negative (n = 6) 4 (67) 2 (33) 0 0 (0) 6 (100) 0 4 (67) 2 (33) 0 1 (17) 3 (50) 2
Positive (n = 2) 2 (100) 0 (0) 0 0 (0) 2 (100) 0 2 (100) 0 (0) 0 1 (50) 1 (50) 0
Lymphoblastic/Burkitt
Negative (n = 6) 6 (100) 0 (0) 0 3 (50) 3 (50) 0 5 (83) 1 (17) 0 5 (83) 1 (17) 0
Positive (n = 10) 10 (100) 0 (0) 0 7 (70) 3 (30) 0 9 (90) 1 (10) 0 5 (50) 5 (50) 0
ND, not done.
* Based on previously published data.24-26 Data are given as number (percentage) unless otherwise indicated.
† Percentage of analyzed cases.
‡ Mean percentage of results of analyzed cases.
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between expression of cyclin D3 and p21Waf1. Furthermore,
we confirmed the existence of a subset of highly proliferative
aggressive lymphomas with coexpression of cyclin D3 and
p27Kip1. A new finding was the association of cyclin D3
expression and increased expression of both p21Waf1 and the
proliferation marker MIB-1. These findings are consistent
with the hypothesis that cyclin D3 can contribute to
lymphomagenesis by interacting with CDKIs. The associa-
tion between cyclin D3 and p21Waf1 further suggests that this
mechanism also could contribute to lymphomagenesis in
subsets of indolent lymphomas, in addition to aggressive
lymphomas, as shown hitherto. Colocalization and functional
studies are needed to provide further insight into this
possible interaction. Our results furthermore confirmed that
mantle cell lymphomas, which overexpress cyclin D1, do not
overexpress cyclin D3,28 indicating functional redundancy of
cyclins D1 and D3 in these lymphomas.
An interesting finding in the present study was the signif-
icantly increased expression of cyclin D3 in indolent lym-
phomas with altered p53 status. An additional novel finding
was that overexpression of the p53-regulatory protein MDM2
correlated with increased cyclin D3 expression. It is not clear
how these results should be interpreted. However, a transgenic
mouse model has shown that cyclin D1 overexpression can
result in p53 abnormalities.29 It therefore has to be considered
that cyclin D3 overexpression also can result in p53 abnormal-
ities or in other ways interact with the p53 system.
The present study is the first to analyze the clinical
significance of cyclin D3 expression in cancer. We found that
cyclin D3 expression correlated with the unfavorable clinical
variables of older age, B symptoms, extranodal disease, and
higher IPI risk group allocation in indolent lymphomas.
However, cyclin D3 expression was associated independently
with a worse prognosis for both overall survival and relapse-
free survival for this group of lymphomas. Thus, our study
indicates that cyclin D3 expression characterizes a fraction of
indolent lymphomas with more aggressive features. Although
most cyclin D3–positive indolent lymphomas attained
complete response or partial remission, the poor relapse-free
survival suggests that lymphoma cells harboring cyclin D3
expression are more difficult to eradicate.
Recent in vitro studies have suggested mechanisms that
may make D-type cyclin overexpressing tumors more
aggressive. In human pancreatic cancer cells, inhibition of
cyclin D1 expression was associated with increased
chemotherapeutic cytotoxicity.30 This was mediated, at least
partly, by decreased expression of the gene products of the
multidrug resistance genes MDR-1 and MRP. Whether
cyclin D3 has the same capabilities is unknown. However,
cyclin D3 overexpression is associated with inhibition of
apoptosis in hematopoietic cells.31,32 Experimental data are
needed to show whether this antiapoptotic function of cyclin
D3 results in increased chemoresistance.
A technical issue also needs to be addressed. The
expression levels of cyclin D3 in reactive lymphoid tissue
and in lymphomas are lower in the present study than in
some previous studies.16,28 However, despite these differ-
ences, the results from the studies are comparable as
evidenced by the staining pattern in benign lymphoid tissues
and the consistent correlation with p27Kip1 in aggressive
lymphomas. Reasons for the differences are variations from
study to study in the immunohistochemical cyclin D3 assay
used and differences in fixation and processing of samples. It
is, therefore, important in each particular laboratory to estab-
lish which cutoff point is most informative in the particular
laboratory setting.
Although our numbers are small, our data suggest that
the immunohistochemical evaluation of cyclin D3 expression
in indolent non-Hodgkin lymphomas may be useful for iden-
tifying patients likely to have an adverse outcome. Therefore,
study is warranted of cyclin D3 expression in larger, prefer-
ably prospective, lymphoma studies with sufficient cases
to allow clinical outcome analyses of distinct lymphoma
entities.
From the 1Department of Pathology, Odense University Hospital,
and 2Institute of Clinical Research, University of Southern
Denmark–Odense University, Odense, Denmark.
❚Table 3❚
(Cont)
p27Kip1 MIB-1
40% or No. Mean No.
<40%† More† ND %‡ ND
0 (0) 12 (100) 1 4 0
1 (8) 11 (92) 2 16 3
1 (33) 2 (67) 1 26 0
12 (48) 13 (52) 1 27 0
2 (100) 0 (0) 0 34 0
5 (31) 11 (69) 0 29 0
2 (67) 1 (33) 0 66 0
12 (75) 4 (25) 2 30 2
— — — — —
33 (89) 4 (11) 1 63 0
8 (73) 3 (27) 0 58 1
8 (44) 10 (56) 0 36 0
5 (45) 6 (54) 0 49 0
6 (100) 0 (0) 0 74 0
2 (100) 0 (0) 0 69 0
6 (100) 0 (0) 0 85 0
6 (60) 4 (40) 0 87 0
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